The disclosure of the 2026 three-quarter reports of A-share medical device listed companies has come to an end. Against the backdrop of a gradual recovery in medical equipment procurement, deepening reform of DRG/DIP medical insurance payment methods, and normalization of high-value consumables collection, the industry showed distinct characteristics of differentiation: the revenue of leading equipment companies continued to grow, but profits were pressured by factors such as exchange and expenses; profits of in vitro diagnostic companies improved; and companies in the field of high-value consumables were differentiated in collection. Overseas business has become an important growth support for leading companies. Some industry insiders interviewed believe that this round of recovery is a structural restoration of “tiered bottom-up” rather than a general rise in the entire sector.

The disclosure of the 2026 three-quarter reports of A-share medical device listed companies has come to an end. Against the backdrop of a gradual recovery in medical equipment procurement, deepening reform of DRG/DIP medical insurance payment methods, and normalization of high-value consumables collection, the industry showed distinct characteristics of differentiation: the revenue of leading equipment companies continued to grow, but profits were pressured by factors such as exchange and expenses; profits of in vitro diagnostic companies improved; and companies in the field of high-value consumables were differentiated in collection. Overseas business has become an important growth support for leading companies. Some industry insiders interviewed believe that this round of recovery is a structural restoration of “tiered bottom-up” rather than a general rise in the entire sector.